Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Aptose Biosciences ( (TSE:APS) ).
On February 23, 2026, Aptose Biosciences amended and restated its November 18, 2025 arrangement agreement with Hanmi Pharmaceutical’s subsidiary HS North America to continue under Alberta corporate law and proceed with a statutory plan of arrangement under which Hanmi will acquire all Aptose shares it does not already own. The revision mainly postpones the special shareholder meeting from January 16, 2026 to March 31, 2026, with the board unanimously urging investors to back the deal as the company responds to U.S. SEC comments and circulates updated proxy materials.
On the same date, Aptose and Hanmi entered into a US$11.1 million second amended and restated facility agreement, providing multiple advances at 6% interest through mid‑2026 to fund business and clinical expenses tied to tuspetinib. The related‑party financing, approved under a financial hardship exemption, underscores Aptose’s reliance on Hanmi for liquidity as the acquisition process unfolds, with implications for minority shareholders’ influence and the company’s capital structure.
The most recent analyst rating on (TSE:APS) stock is a Hold with a C$2.50 price target. To see the full list of analyst forecasts on Aptose Biosciences stock, see the TSE:APS Stock Forecast page.
Spark’s Take on TSE:APS Stock
According to Spark, TipRanks’ AI Analyst, TSE:APS is a Neutral.
The score is held back primarily by very weak financial performance (no revenue, ongoing cash burn, negative equity and rising debt). Positive corporate catalysts (promising trial results and a pending acquisition) provide meaningful offset, while technical indicators are mixed-to-weak and valuation metrics are not supportive due to negative earnings and no dividend.
To see Spark’s full report on TSE:APS stock, click here.
More about Aptose Biosciences
Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on precision medicines for oncology, with an initial emphasis on hematologic cancers. Its pipeline of small‑molecule cancer therapeutics is designed for single‑agent use and to boost other anti‑cancer regimens, led by tuspetinib, an oral kinase inhibitor being developed for frontline triplet therapy in newly diagnosed acute myeloid leukemia and in relapsed or refractory AML.
Average Trading Volume: 5,093
Technical Sentiment Signal: Sell
Current Market Cap: C$5.74M
See more data about APS stock on TipRanks’ Stock Analysis page.